Pull to refresh
Logo
Lilly's oral GLP-1 Foundayo clears cardiovascular safety bar in largest type 2 diabetes trial

Lilly's oral GLP-1 Foundayo clears cardiovascular safety bar in largest type 2 diabetes trial

New Capabilities

ACHIEVE-4 results position the pill against injectables and oral semaglutide as an FDA decision nears

Yesterday: Full ACHIEVE-4 results reaffirm safety and sustained metabolic gains

Overview

Updated 1 hour ago

Millions with type 2 diabetes manage blood sugar with daily injections. Lilly's Foundayo (orforglipron) is a pill that could replace them — and in its largest trial it matched insulin on heart safety while cutting weight and blood sugar more.

The drug is the leading small-molecule oral GLP-1, a once-daily pill with no fasting rules, unlike Novo Nordisk's Rybelsus. An FDA approval could shift first-line diabetes care, and a separate obesity program opens a far larger weight-loss market.

Why it matters

If approved, an oral GLP-1 with no fasting rules could replace daily injections for millions, pressuring Novo Nordisk's semaglutide franchise.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

16%
Lower risk of MACE-4 events vs insulin glargine
Heart attack, stroke, cardiovascular death, or hospitalization for unstable chest pain (hazard ratio 0.84).
57%
Lower risk of all-cause death vs insulin glargine
Pre-planned analysis; not controlled for multiplicity (nominal p = 0.002).
-8.8%
Body weight change at 52 weeks
Compared with +1.7% for insulin glargine, from a baseline of 90.9 kg.
-1.6%
A1C change at 52 weeks
Compared with -1.0% for insulin glargine, from a baseline of 8.22%.
2,749
ACHIEVE-4 trial participants
Enrolled across 15 countries; the largest and longest Foundayo study to date.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

April 2026 September 2026

3 events Latest: Yesterday
  1. Full ACHIEVE-4 results reaffirm safety and sustained metabolic gains

    Latest Trial Results

    Lilly detailed 16% lower MACE-4 risk and 53% lower cardiovascular death risk, with A1C and weight benefits persisting through 104 weeks.

  2. EASD indirect comparison favors Foundayo over oral semaglutide 25 mg

    Conference Presentation

    Analysis of ACHIEVE-3 and PIONEER PLUS data showed greater A1C and weight reduction for Foundayo 17.2 mg at 52 weeks.

  3. ACHIEVE-4 topline shows non-inferior heart risk, 57% lower death

    Trial Results

    Lilly reported orforglipron matched insulin glargine on heart safety and beat it on A1C and weight; FDA submission planned by end of Q2.

Scenarios

1

FDA approves Foundayo for type 2 diabetes

Likely Resolves by Q2 2027

Discussed by: Lilly company statements; analysts covering the diabetes market

Lilly said it planned to file by the end of Q2 2026 under a Priority Review Voucher. If the FDA accepts the application with priority review, a decision could land within roughly six to ten months. Approval would make orforglipron the first small-molecule oral GLP-1 with no fasting requirement.

2

FDA approval for obesity extends Foundayo beyond diabetes

Possible Resolves by Q2 2028

Discussed by: Lilly's ATTAIN program; obesity market analysts

Lilly is running the ATTAIN program studying orforglipron for chronic weight management. Success would put the pill into the broader obesity market, where oral dosing could draw patients who avoid injectable weight-loss drugs. The timeline for a filing and decision would follow the diabetes approval.

3

Foundayo overtakes oral semaglutide in US prescriptions

Possible Resolves by End of 2028

Discussed by: Market analysts; EASD indirect comparison data

Indirect comparisons show Foundayo 17.2 mg delivers more A1C reduction and weight loss than oral semaglutide 25 mg, with no fasting rules. If approved, prescription share will reveal whether the pill becomes the standard oral GLP-1 or whether Novo's brand loyalty holds.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2017-2021

Semaglutide becomes a blockbuster (2017-2021)

Novo Nordisk's injectable semaglutide, sold as Ozempic for diabetes and Wegovy for obesity, turned GLP-1 drugs into the best-selling medicine class in the world.

Then

Demand for weight-loss drugs outstripped supply and drove Novo's valuation past most European companies.

Now

The category's scale drew Lilly and others into a fierce race for the next generation of oral options.

Why this matters now

The blockbuster market shows what an oral competitor stands to capture and why Lilly pushed orforglipron through a huge cardiovascular trial before filing.

September 2019

Rybelsus oral semaglutide launch (2019)

The FDA approved Rybelsus, the first oral GLP-1 drug, for type 2 diabetes. Patients had to fast 30 minutes before and after each dose and take it on an empty stomach, which limited convenience.

Then

Rybelsus sold far below Novo's injectable Ozempic, whose once-weekly dosing dominated.

Now

It proved an oral GLP-1 could work, setting the stage for small-molecule versions without the fasting burden.

Why this matters now

Orforglipron targets the same mechanism but removes the fasting requirement and shows stronger results in indirect comparisons, attacking the exact weakness that held Rybelsus back.

Sources

(8)